ChromaDex Corporation (CDXC) |
7.87 -0.07 (-0.88%) 03-18 16:00 |
Open: | 7.91 |
High: | 7.92 |
Low: | 7.745 |
Volume: | 541,672 |
Market Cap: | 612(M) |
PE Ratio: | 71.55 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 11.10 |
Resistance 1: | 9.50 |
Pivot price: | 7.87 |
Support 1: | 6.92 |
Support 2: | 5.33 |
52w High: | 9.18 |
52w Low: | 2.305 |
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
EPS | 0.110 |
Book Value | 0.600 |
PEG Ratio | 0.00 |
Gross Profit | 0.792 |
Profit Margin (%) | 8.59 |
Operating Margin (%) | 24.42 |
Return on Assets (ttm) | 7.8 |
Return on Equity (ttm) | 22.9 |
Tue, 25 Mar 2025
Why ChromaDex Corp (CDXC) Is Surging In 2025? - Yahoo Finance
Thu, 13 Mar 2025
ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com
Thu, 13 Mar 2025
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Business Wire
Thu, 06 Mar 2025
ChromaDex Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Thu, 06 Mar 2025
ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha
Wed, 05 Mar 2025
ChromaDex Stock Jumps: Unpacking The Surge - StocksToTrade
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |